Chemotherapy Use, Performance Status, and Quality of Life at the End of Life
- PMID: 26203912
- PMCID: PMC4828728
- DOI: 10.1001/jamaoncol.2015.2378
Chemotherapy Use, Performance Status, and Quality of Life at the End of Life
Abstract
Importance: Although many patients with end-stage cancer are offered chemotherapy to improve quality of life (QOL), the association between chemotherapy and QOL amid progressive metastatic disease has not been well-studied. American Society for Clinical Oncology guidelines recommend palliative chemotherapy only for solid tumor patients with good performance status.
Objective: To evaluate the association between chemotherapy use and QOL near death (QOD) as a function of patients' performance status.
Design, setting, and participants: A multi-institutional, longitudinal cohort study of patients with end-stage cancer recruited between September 2002 and February 2008. Chemotherapy use (n = 158 [50.6%]) and Eastern Cooperative Oncology Group (ECOG) performance status were assessed at baseline (median = 3.8 months before death) and patients with progressive metastatic cancer (N = 312) following at least 1 chemotherapy regimen were followed prospectively until death at 6 outpatient oncology clinics in the United States.
Main outcomes and measures: Patient QOD was determined using validated caregiver ratings of patients' physical and mental distress in their final week.
Results: Chemotherapy use was not associated with patient survival controlling for clinical setting and patients' performance status. Among patients with good (ECOG score = 1) baseline performance status, chemotherapy use compared with nonuse was associated with worse QOD (odds ratio [OR], 0.35; 95% CI, 0.17-0.75; P = .01). Baseline chemotherapy use was not associated with QOD among patients with moderate (ECOG score = 2) baseline performance status (OR, 1.06; 95% CI, 0.51-2.21; P = .87) or poor (ECOG score = 3) baseline performance status (OR, 1.34; 95% CI, 0.46-3.89; P = .59).
Conclusions and relevance: Although palliative chemotherapy is used to improve QOL for patients with end-stage cancer, its use did not improve QOD for patients with moderate or poor performance status and worsened QOD for patients with good performance status. The QOD in patients with end-stage cancer is not improved, and can be harmed, by chemotherapy use near death, even in patients with good performance status.
Figures

Comment in
-
Chemotherapy Near the End of Life: First--and Third and Fourth (Line)--Do No Harm.JAMA Oncol. 2015 Sep;1(6):785-6. doi: 10.1001/jamaoncol.2015.2379. JAMA Oncol. 2015. PMID: 26203585 No abstract available.
-
Chemotherapy does not improve quality of life in cancer patients at end of life, US study finds.BMJ. 2015 Jul 30;351:h4139. doi: 10.1136/bmj.h4139. BMJ. 2015. PMID: 26228874 No abstract available.
-
Evaluating Chemotherapy at the End of Life.JAMA Oncol. 2016 Jan;2(1):142. doi: 10.1001/jamaoncol.2015.4102. JAMA Oncol. 2016. PMID: 26767554 No abstract available.
-
Evaluating Chemotherapy at the End of Life.JAMA Oncol. 2016 Jan;2(1):142-3. doi: 10.1001/jamaoncol.2015.4105. JAMA Oncol. 2016. PMID: 26767555 No abstract available.
-
Evaluating Chemotherapy at the End of Life.JAMA Oncol. 2016 Jan;2(1):143-4. doi: 10.1001/jamaoncol.2015.4108. JAMA Oncol. 2016. PMID: 26767556 No abstract available.
-
Evaluating Chemotherapy at the End of Life--Reply.JAMA Oncol. 2016 Jan;2(1):144. doi: 10.1001/jamaoncol.2015.4111. JAMA Oncol. 2016. PMID: 26767559 No abstract available.
Similar articles
-
Impact of Radiation Therapy on Aggressive Care and Quality of Life Near Death.J Pain Symptom Manage. 2017 Jan;53(1):25-32. doi: 10.1016/j.jpainsymman.2016.08.011. Epub 2016 Oct 5. J Pain Symptom Manage. 2017. PMID: 27720786 Free PMC article.
-
Palliative chemotherapy for gastroesophageal cancer in old and very old patients: A retrospective cohort study at the National Center for Tumor Diseases, Heidelberg.World J Gastroenterol. 2015 Apr 28;21(16):4911-8. doi: 10.3748/wjg.v21.i16.4911. World J Gastroenterol. 2015. PMID: 25945004 Free PMC article.
-
Chemotherapy does not improve quality of life in cancer patients at end of life, US study finds.BMJ. 2015 Jul 30;351:h4139. doi: 10.1136/bmj.h4139. BMJ. 2015. PMID: 26228874 No abstract available.
-
Assessment of quality of life during chemotherapy.Acta Oncol. 2001;40(2-3):175-84. doi: 10.1080/02841860151116222. Acta Oncol. 2001. PMID: 11441930 Review.
-
Chemotherapy at end-of-life: an integration of oncology and palliative team.Support Care Cancer. 2016 Mar;24(3):1421-7. doi: 10.1007/s00520-015-3031-z. Epub 2015 Nov 25. Support Care Cancer. 2016. PMID: 26604192 Review.
Cited by
-
Ferrite Nanoparticles-Based Reactive Oxygen Species-Mediated Cancer Therapy.Front Chem. 2021 Apr 27;9:651053. doi: 10.3389/fchem.2021.651053. eCollection 2021. Front Chem. 2021. PMID: 33987168 Free PMC article. Review.
-
Change of genitourinary cancer patients' perception and expectations over the course of pharmacotherapy.PLoS One. 2022 Nov 22;17(11):e0278039. doi: 10.1371/journal.pone.0278039. eCollection 2022. PLoS One. 2022. PMID: 36413565 Free PMC article.
-
Comparison of Health Care Utilization at the End of Life Among Patients With Cancer in Alberta, Canada, Versus Washington State.JCO Oncol Pract. 2020 Dec;16(12):e1543-e1552. doi: 10.1200/OP.20.00217. Epub 2020 Aug 17. JCO Oncol Pract. 2020. PMID: 32804586 Free PMC article.
-
Association Between Spending and Outcomes for Patients With Cancer.J Clin Oncol. 2020 Feb 1;38(4):323-331. doi: 10.1200/JCO.19.01451. Epub 2019 Dec 5. J Clin Oncol. 2020. PMID: 31804868 Free PMC article. Review. No abstract available.
-
Continuing, Withdrawing, and Withholding Medical Treatment at the End of Life and Associated Characteristics: a Mortality Follow-back Study.J Gen Intern Med. 2020 Jan;35(1):126-132. doi: 10.1007/s11606-019-05344-5. Epub 2019 Oct 25. J Gen Intern Med. 2020. PMID: 31654360 Free PMC article.
References
-
- Kelly RJ, Smith TJ. Delivering maximum clinical benefit at an affordable price: engaging stakeholders in cancer care. Lancet Oncol. 2014;15(3):e112–e118. doi:10.1016/S1470-2045(13)70578-3. Published online February 14, 2014. - PubMed
-
- Meier DE. ‘I don’t want Jenny to think I’m abandoning her’: views on overtreatment. Health Aff (Millwood) 2014;33(5):895–898. - PubMed
-
- Bach PB. [Accessed June 10, 2015];The day I started lying to Ruth. 2014 http://nymag.com/news/features/cancer-peter-bach-2014-5/
-
- Braga S. Why do our patients get chemotherapy until the end of life? Ann Oncol. 2011;22(11):2345–2348. - PubMed
-
- Anders CK, Peppercorn J. Treating in the dark: unanswered questions on costs and benefits of late line therapy for metastatic breast cancer. Cancer Invest. 2009;27(1):13–16. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical